Filing Flows › Companies › Maze Therapeutics › Report card
Maze Therapeutics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate2 of 3 reports beat the EPS estimate
Maze Therapeutics (MAZE) beat the analysts' EPS estimate in 2 of its last 3 reports (67%), by +0.4% on average. Next report: Nov 9, 2026, analysts expect EPS −$0.75.
Beat rate67% of 3
Average surprise+0.4%
Next reportNov 9, 2026
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise |
|---|---|---|---|---|
| Q to Jun 2026 | Aug 11, 2026 | −$0.70 | −$0.76 | -9.2% |
| Q to Dec 2025 | Mar 25, 2026 | −$0.69 | −$0.65 | +5.7% |
| Q to Sep 2025 | Nov 6, 2025 | −$0.69 | −$0.66 | +4.7% |
Estimates and reported EPS are the Street's adjusted figures. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Maze Therapeutics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.